Is it possible to treat Renal cell carcinoma with Immune based therapy?

With the help of this blog we are going to let you know about the possibility of treating renal cell carcinoma with immune based therapy. Immunotherapy is one of the growing fields in cancer research in recent years. Renal cell carcinoma (RCC) is the most common type of renal cancer in adults that originates from the lining of proximal convoluted tubule (PCT) in the kidney. 

 

www.gapsos.com

According to the data presented by the SEER in 2014, it was estimated that approximately 63,920 new cases of renal cancer (39,140 in men and 24,780 in women) were identified and about 13,860 people (8,900 men and 4,960 women) get died from this disease in the U.S. The incidence and prevalence in males and females is in the ratio 1.5:1. 

The prevalence was estimated that there were 358,603 people alive with RCC in the United States in 2011. The RCC represents 3.8% of all cancer cases in the United States. 

The most common risk factors are body weight, smoking, hazards chemicals such as cadmium, and herbicide, inherited risk factors such as von Hippel Lindau disease, hereditary leiomyoma renal cell carcinoma, hereditary papillary renal cell carcinoma, and hereditary renal oncocytoma, and other risk factors are race, gender, high blood pressure and family history.

The treatment protocol includes monoclonal antibodies, kinase inhibitors, mTOR therapy, vaccines and proteasome inhibitor therapy.

The FDA approved monoclonal antibodies is Bevacizumab. 

In kinase inhibitors the FDA approved drugs are Sunitinib Malate, Sorafenib, Pazopanib, and Axitinib.

The FDA approved mTOR drug is Temsirolimus and Everolimus.

There are some vaccines that are not currently approved by FDA for RCC. However, many drugs are under clinical trials in phase I, II, and III such as AGS-003 and IL-2 (Aldesleukin).

There are some proteasome inhibitor drugs that are not currently approved by FDA for RCC. However, many drugs are under clinical trials in phase I, II, and III as Bortezomib and Carfilzomib.

Immunotherapy has proven to be effective in the treatment of renal cell carcinoma (RCC). Our success in treating RCC is increasing and advancing with the knowledge of the function of the immune system.

Global Allied Pharmaceuticals (GAP) has advanced treatment based on immunotherapy and immune combination therapy for various types of cancer. Additionally our company accompanies an expert and skilled team of researchers and oncologists which works effectively to meet the unmet meet of medication.